Top

Published in:

01-07-2014 | Original Article

Salvage lymphadenectomy without esophagectomy is an option for recurrent or residual lymph nodes after definitive chemoradiotherapy for esophageal cancer

Authors: Satoru Matono, Hiromasa Fujita, Toshiaki Tanaka, Naoki Mori, Takeshi Nagano, Kohei Nishimura, Haruhiro Hino, Kazuo Shirouzu, Hidehiro Eto, Etsuyo Ogo, Takashi Yanagawa

Published in: Esophagus | Issue 3/2014

Abstract

Purposes

The aim of this study was to determine the prognostic factors in salvage surgery following definitive chemoradiotherapy (dCRT) for esophageal cancer.

Methods

We retrospectively reviewed twenty-five patients who underwent salvage surgery from 1986 to 2011 at Kurume University Hospital.

Results

Esophagectomy was adopted for 20 patients, while lymphadenectomy alone without esophagectomy was adopted for the other 5 patients. Univariate analysis found that age, response to initial treatment, presence of residual tumor, pT after salvage surgery, and severe complications were each significantly correlated with overall survival after salvage surgery. The type of surgery (esophagectomy vs lymphadenectomy) and presence of residual tumor (R) were each determined to be an independent prognostic factor by the multivariate analysis. Namely, the prognosis after R0 resection was better than that after R1/2 resection (HR 18.050, p < 0.0001), and the prognosis after salvage lymphadenectomy was better than that after salvage esophagectomy (HR 5.091, p = 0.0086).

Conclusions

Salvage lymphadenectomy without esophagectomy is suggested to be an option for patients having recurrent or residual lymph nodes without any other recurrence or residual tumor after dCRT for esophageal cancer.

Akiyama H, Tsurumaru M, Udagawa H, Kajiyama Y. Radical lymph node dissection for cancer of the thoracic esophagus. Ann Surg. 1994;220:364–73.PubMedCentralPubMedCrossRef

Fujita H, Kakegawa T, Yamana H, Shima I, Toh Y, Tomita Y, et al. Mortality and morbidity rates, postoperative course, quality of life, and prognosis after extended radical lymphadenectomy for esophageal cancer: comparison of three-field lymphadenectomy with two-field lymphadenectomy. Ann Surg. 1995;222:654–62.PubMedCentralPubMedCrossRef

Fujita H, Sueyoshi S, Tanaka T, Shirouzu K. Three-field dissection for squamous cell carcinoma in the thoracic esophagus. Ann Thorac Cardiovasc Surg. 2002;8:328–35.PubMed

Murakami M, Kuroda Y, Nakajima T, Okamoto Y, Mizowaki T, Kusumi F, et al. Comparison between chemoradiation protocol intended for organ preservation and conventional surgery for clinical T2-1 esophageal carcinoma. Int J Radiat Oncol Biol Phys. 1999;45:277–84.PubMedCrossRef

Igaki H, Kato H, Tachimori Y, Daiko H, Fukaya M, Yajima S, et al. Clinicopathologic characteristics and survival of patients with clinical Stage I squamous cell carcinomas of the thoracic esophagus treated with three-field lymph node dissection. Eur J Cardiothorac Surg. 2001;20:1089–94.PubMedCrossRef

Hironaka S, Ohtsu A, Boku N, Muto M, Nagashima F, Saito H, et al. Nonrandmized comparison between definitive chemoradiotherapy and radical surgery in patients with T2-3 Nany M0 squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys. 2003;57:425–33.PubMedCrossRef

Kato H, Sato A, Fukuda H, Kagami Y, Udagawa H, Togo A, et al. A phase II trial of chemoradiotherapy for Stage I esophageal squamous cell carcinoma: Japan Clinical Oncology Group Study (JCOG9708). Jpn J Clin Oncol. 2009;39:638–43.PubMedCrossRef

Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, et al. INT 0123 (Radiation Therapy Oncology Group 94–05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002;20:1167–74.PubMedCrossRef

Ohtsu A. Chemoradiotherapy for esophageal cancer: current status and perspectives. Int J Clin Oncol. 2004;9:444–50.PubMedCrossRef

10.

Kavanagh B, Anscher M, Leopold K, Deutsch M, Gaydica E, Dodge R, et al. Patterns of failure following combined modality therapy for esophageal cancer, 1984–1990. Int J Radiat Oncol Biol Phys. 1992;24:633–42.PubMedCrossRef

11.

Gill PG, Denham JW, Jamieson GG, Devitt PG, Yeoh E, Olweny C. Pattern of treatment failure and prognostic factors associated with the treatment of esophageal carcinoma with chemotherapy and radiotherapy either as sole treatment followed by surgery. J Clin Oncol. 1992;10:1037–43.PubMed

12.

Meunier B, Raoul J, Le Prisé E, Lakéhal M, Launois B. Salvage esophagectomy after unsuccessful curative chemoradiotherapy for squamous cell cancer of the esophagus. Dig Surg. 1998;15:224–6.PubMedCrossRef

13.

Wynn P, Putnam JB, Mosheim MB, Correa AM, Komaki RR, et al. Salvage esophagectomy for recurrent tumors after definitive chemotherapy and radiotherapy. J Thorac Cardiovasc Surg. 2002;123:175–83.PubMedCrossRef

14.

Urschel JD, Sellke FW. Complications of salvage esophagectomy. Med Sci Monit. 2003;9:RA173–80.PubMed

15.

Tomimaru Y, Yano M, Takachi K, Miyashiro I, Ishihara R, Nishiyama K, et al. Factors affecting the prognosis of patients with esophageal cancer undergoing salvage surgery after definitive chemoradiation. J Surg Oncol. 2006;93:422–8.PubMedCrossRef

16.

Sobin LH, Wittekind CH, editors. UICC International Union Against Cancer. Esophagus (ICD-O C15). TMN classification of malignant tumors. 6th ed. New York: Wiley-Liss; 2002.

17.

Japan Esophageal Society. Japanese classification of esophageal cancer. 10th ed. Tokyo: Kanehara; 2008.

18.

Akaike H. Information theory and an extension of the maximum likelihood principle. In: Petrov BN, Csalki F, editors. 2nd international symposium on information theory. Budapest: Akademiai Kiado; 1973. pp. 267–81.

19.

Murakami M, Kuroda Y, Okamoto Y, Kono K, Yoden E, Kusumi F, et al. Neoadjuvant concurrent chemoradiotherapy followed by definitive high-dose radiotherapy or surgery for operable thoracic esophageal carcinoma. Int J Radiat Oncol Biol Phys. 1998;40:1049–59.PubMedCrossRef

20.

Ohtsu A, Boku N, Muro K, Chin K, Muto M, Yoshida S, et al. Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol. 1999;17:2915–21.PubMed

21.

Bidoli P, Bajetta E, Stani SC, De CD, Santoro A, Valente M, et al. Ten-year survival with chemotherapy and radiotherapy in patients with squamous cell carcinoma of the esophagus. Cancer. 2002;94:352–61.PubMedCrossRef

22.

Ueda Y, Fujii Y, Udagawa H. Thoracic and cardiovascular surgery in Japan during 2006—Annual report by the Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg. 2008;56:365–88.PubMedCrossRef

23.

Makuuchi H, Tsurumaru M. Symposium 1. Salvage surgery for cancer of the esophagus—its definition and outcomes. Esophagus. 2004;1:177–8.CrossRef

24.

Gardner-Thorpe J, Hardwick RH, Dwerryhouse SJ. Salvage esophagectomy after local failure of definitive chemoradiotherapy. Br J Surg. 2007;94:1059–66.PubMedCrossRef

25.

Nishimura M, Daiko H, Yoshida J, Nagai K. Salvage esophagectomy following definitive chemoradiotherapy. Gen Thorac Cardiovasc Surg. 2007;55:461–5.PubMedCrossRef

26.

Oki E, Morita M, Kakeji Y, Ikebe M, Sadanaga N, Egasira A, et al. Salvage esophagectomy after definitive chemoradiotherapy for esophageal cancer. Dis Esophagus. 2007;20:301–4.PubMedCrossRef

27.

Akutsu Y, Matsubara H, Shuto K, Uesato M, Mori M, Hoshino I, et al. Clinical and pathologic evaluation of the effectiveness of neoadjuvant chemoradiation therapy in advanced esophageal cancer patients. World J Surg. 2009;33:1002–9.PubMedCrossRef

28.

Matono S, Tanaka T, Tanaka Y, Nagano T, Nishimura K, Murata K, et al. Salvage esophagectomy after definitive chemoradiotherapy for esophageal cancer (in Japanese with English abstract). Jpn J Gastroenterol Surg. 2010;43:1089–97.CrossRef

29.

Nakamura T, Hayashi K, Ota M, Narumiya K, Eguchi R, Ide H, et al. Salvage surgery after definitive chemoradiotherapy for esophageal cancer. Esophagus. 2005;2:123–8.CrossRef

30.

Sato H, Tsubosa Y, Ito I. Early recurrence after salvage surgery following definitive chemoradiotherapy for esophageal cancer (in Japanese with English abstract). Jpn J Gastroenterol Surg. 2005;38:25–30.CrossRef

31.

Seto Y, Fukuda T, Yamada K, Matsubara T, Chin K, Kumada M, et al. Significance and problem of salvage surgery after definitive chemoradiotherapy for esophageal carcinoma (in Japanese with English abstract). Jpn J Cancer Clin. 2007;53:641–5.

32.

Doki Y, Yasuda T, Miyata H, Fujiwara Y, Takiguchi S, Yamasaki M, et al. Salvage lymphadenectomy of the right recurrent nerve node with tracheal involvement after definitive chemoradiation therapy for esophageal squamous cell carcinoma: report of two cases. Surg Today. 2007;37:590–5.PubMedCrossRef

33.

Yoshimura F, Sakurai Y, Furuta S, Sunagawa R, Inaba K, Isogaki J, et al. Lymph node dissection with cervical approach as a salvage surgery for locoregional failure after definitive chemoradiotherapy in a patient with recurrent esophageal carcinoma: report of a case. Esophagus. 2009;6:55–61.CrossRef

34.

Kawanishi K, Ho H, Shinkai M, Hirai N, Imano M, Shigeoka H, et al. Surgical treatment for recurrence of esophageal cancer (in Japanese). J Clin Surg. 2005;60:187–92.

35.

Kawano T, Nakajima Y, Suzuki T, Haruki S, Ogiya K, Kawada K, et al. Esophageal carcinoma—from the viewpoint of surgery (in Japanese with English abstract). Jpn J Cancer Chemother. 2007;34:824–30.

Title: Salvage lymphadenectomy without esophagectomy is an option for recurrent or residual lymph nodes after definitive chemoradiotherapy for esophageal cancer
Authors: Satoru Matono
Hiromasa Fujita
Toshiaki Tanaka
Naoki Mori
Takeshi Nagano
Kohei Nishimura
Haruhiro Hino
Kazuo Shirouzu
Hidehiro Eto
Etsuyo Ogo
Takashi Yanagawa
Publication date: 01-07-2014
Publisher: Springer Japan
Published in: Esophagus / Issue 3/2014
Print ISSN: 1612-9059
Electronic ISSN: 1612-9067
DOI: https://doi.org/10.1007/s10388-014-0430-z

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Salvage lymphadenectomy without esophagectomy is an option for recurrent or residual lymph nodes after definitive chemoradiotherapy for esophageal cancer

Abstract

Purposes

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purposes

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2014

A phase II study of nedaplatin and 5-fluorouracil in metastatic squamous cell carcinoma of the esophagus: The Japan Clinical Oncology Group (JCOG) Trial (JCOG 9905-DI)

E-cadherin expression in Barrett’s esophagus and esophageal carcinoma

A case of superficial esophageal carcinoma with papilloma resected by en bloc endoscopic submucosal dissection

Neoadjuvant chemotherapy using concurrent Docetaxel/CDDP/5-FU (DCF) in esophageal squamous cell carcinoma and its short-term prognosis

Should lymph nodes along the thoracic duct be dissected routinely in radical esophagectomy?

Effectiveness of polymyxin B-direct hemoperfusion (PMX-DHP) therapy using a polymyxin B-immobilized fiber column in patients with post-esophagectomy sepsis

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page